Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.
- Details
- Category: Business
Sanofi and Astellas Pharma Inc. announced that the two companies agreed to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc., a joint company of Sanofi and Astellas.
Pfizer acquires Alacer Corp., a leading vitamin supplements company
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.
Sanofi and the Institut Pasteur create four prestigious awards
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and the Institut Pasteur announced the creation of the Sanofi-Institut Pasteur Awards to encourage scientific excellence in the service of health.
Merck announces efficiency program across all businesses and regions
- Details
- Category: Merck Group
Merck's Executive Board presented initial plans for an efficiency program spanning all businesses and regions to the Supervisory Board and relevant employee representative bodies.
Boehringer Ingelheim and Xencor enter a collaboration agreement
- Details
- Category: Boehringer Ingelheim
Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced a collaboration agreement for certain Xencor biosuperior monoclonal antibodies.
BRILINTA® added to American College of Chest Physicians recommendations
- Details
- Category: AstraZeneca
AstraZeneca (NYSE: AZN) announced that the American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a recommendation for giving the oral antiplatelet medicine, BRILINTA® (ticagrelor) tablets with low-dose aspirin to patients who suffer from Acute Coronary Syndrome (ACS).
Pfizer and Hisun announce progress on potential joint venture
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceutical (SSE Code: 600267), a leading pharmaceutical company in China, signed a framework agreement, advancing their previously announced memorandum of understanding (MOU) to establish a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.
More Pharma News ...
- Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye
- Bristol-Myers Squibb Foundation Announces Grants Focused on Prevention, Diagnosis and Care of Hepatitis B and Hepatitis C in Asia
- EU and US Regulatory Update - Tykerb/Tyverb® (lapatinib)
- Positive top-line result for UCB's Cimzia® in psoriatic arthritis
- Merck Establishes Joint Venture with Supera Farma
- Lilly releases its most comprehensive corporate responsibility report
- Bristol-Myers Squibb Completes Acquisition of Inhibitex, Inc.